BioIntelligence Technologies believes it has found an optimal way to limit losses in vaccine production. A phenomenon of great interest to several pharmaceuticals, who quickly contacted the Sherbrooke company at the start of the pandemic, last March.
–
In collaboration with the Faculty of Engineering of the University of Sherbrooke, BioIntelligence Technologies has developed a new measurement tool that enables the detection of irregularities in vaccine production in real time.
The process would therefore allow pharmaceutical companies to act immediately to limit losses of the precious liquid, a recurring issue in the biotechnology field.
Typically the losses in biotechnology in bioprocesses can be of the order of 5 to 20%, then in new processes we can speak of 20 to 50%. If we can just impact 10% of production, we have already significantly increased profitability.
, explains Joël Sirois, Chairman and CEO of BioIntelligence Technologies.
Founded in 2014, BioIntelligence Technologies had not planned to enter the pharmaceutical arena so early, but since the last year, agreements have multiplied.
With the future vaccine production plant announced by the federal government this winter, the business opportunities are great.
It is expected that in the coming months it should have production in the Montreal area, in the new plant, for which the government has invested tens, hundreds of millions.
It is in this Montreal plant that the American pharmaceutical company Novavax wants to produce tens of millions of doses of its candidate vaccine against COVID-19.
–
